Capital Advisory Group Advisory Services LLC Increases Stake in Amgen Inc. (NASDAQ:AMGN)

Capital Advisory Group Advisory Services LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,702 shares of the medical research company’s stock after acquiring an additional 118 shares during the quarter. Capital Advisory Group Advisory Services LLC’s holdings in Amgen were worth $704,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently bought and sold shares of AMGN. AMF Tjanstepension AB boosted its position in shares of Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock worth $38,825,000 after purchasing an additional 17,387 shares during the period. Swedbank AB lifted its stake in shares of Amgen by 1.1% during the 3rd quarter. Swedbank AB now owns 538,899 shares of the medical research company’s stock valued at $173,639,000 after buying an additional 5,751 shares in the last quarter. Segment Wealth Management LLC boosted its holdings in Amgen by 5.6% in the 3rd quarter. Segment Wealth Management LLC now owns 938 shares of the medical research company’s stock worth $302,000 after buying an additional 50 shares during the period. Elevated Capital Advisors LLC increased its stake in Amgen by 2.5% in the 3rd quarter. Elevated Capital Advisors LLC now owns 1,539 shares of the medical research company’s stock worth $496,000 after buying an additional 38 shares in the last quarter. Finally, Lake Street Private Wealth LLC raised its holdings in Amgen by 10.1% during the third quarter. Lake Street Private Wealth LLC now owns 1,861 shares of the medical research company’s stock valued at $600,000 after acquiring an additional 171 shares during the period. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Trading Up 1.2 %

AMGN opened at $297.93 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock’s fifty day moving average is $275.62 and its two-hundred day moving average is $300.75. The company has a market capitalization of $160.05 billion, a P/E ratio of 39.46, a PEG ratio of 2.54 and a beta of 0.56. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Analysts forecast that Amgen Inc. will post 20.6 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This represents a $9.52 annualized dividend and a dividend yield of 3.20%. The ex-dividend date is Friday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio is presently 126.09%.

Wall Street Analyst Weigh In

AMGN has been the subject of a number of recent analyst reports. Wells Fargo & Company dropped their price objective on Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Citigroup dropped their price objective on shares of Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Piper Sandler Companies reissued an “overweight” rating and set a $310.00 price objective on shares of Amgen in a research note on Thursday, January 2nd. Finally, William Blair restated an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $314.09.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,589 shares of the company’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total transaction of $483,802.83. Following the completion of the sale, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. This represents a 18.06 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, EVP Murdo Gordon sold 8,771 shares of Amgen stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $294.79, for a total value of $2,585,603.09. Following the completion of the transaction, the executive vice president now owns 44,186 shares in the company, valued at $13,025,590.94. This trade represents a 16.56 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 35,405 shares of company stock worth $10,410,596. Corporate insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.